Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), a biotechnology company
focused on discovering and developing novel antibody immunotherapies
that help the immune system fight cancer and other diseases, today
announced that the company will present a poster titled “Human
Tumor-Based Identification of Immune Checkpoint Targets” at The
University of Texas MD Anderson Cancer Center’s Emerging Concepts in
Host Response to Cancer Symposium Symposia. Enumeral’s poster will
highlight recent developments in the company’s PD-1 and TIM-3 antibody
programs. The poster will be presented at MD Anderson Cancer Center’s R.
Lee Clark Clinic, 1515 Holcombe Boulevard, Floor 11, in Houston, Texas
on October 8, 2015.
About Enumeral
Enumeral is a biopharmaceutical company discovering and developing novel
antibody immunotherapies that help the immune system fight cancer and
other diseases. The Company is building a pipeline focused on
next-generation checkpoint modulators, with initial targets including
PD-1, TIM-3, LAG-3, OX40, and VISTA. In developing these agents,
Enumeral’s researchers apply a proprietary immune profiling technology
platform that measures functioning of the human immune system at the
level of individual cells, providing key insights for candidate
selection and validation. For more information on Enumeral, please visit www.enumeral.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151005005395/en/
Copyright Business Wire 2015